Filing Flows › Idexx Laboratories (IDXX) › Guidance history
Idexx Laboratories (IDXX) guidance history: what it guided and what it reported
Idexx Laboratories gave guidance in 12 earnings releases on file since May 1, 2024. Of 6 guided periods since reported, it met or beat its own guidance 4 times (67%). Revenue: 2 of 2, on average +0.5% against the guided midpoint. Its releases raised guidance 6 times and lowered it once.
Revenue
Met or beat 2 of 2 periods (1 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $4.6B–$4.7B (Feb 2, 2026) → raised $4.7B–$4.8B (May 5, 2026) → reaffirmed $4.7B–$4.7B (Aug 4, 2026) → raised $4.7B–$4.8B (Nov 2, 2026) | — | to be reported | — |
| FY2025 | $3.9B–$4.0B (May 1, 2024) → raised $4.1B–$4.2B (Feb 3, 2025) → raised $4.1B–$4.2B (May 1, 2025) → raised $4.2B–$4.3B (Aug 4, 2025) → raised $4.3B–$4.3B (Nov 3, 2025) | $4.3B | within the range | +0.4% |
| FY2024 | $3.9B–$3.9B (Aug 6, 2024) → lowered $3.9B–$3.9B (Oct 31, 2024) | $3.9B | above the range | +0.5% |
GAAP operating margin
Met or beat 2 of 2 periods (0 above, 2 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 32.1%–32.5% (May 5, 2026) → raised 32.3%–32.5% (Aug 4, 2026) → lowered 32.1%–32.3% (Nov 2, 2026) | — | to be reported | — |
| FY2025 | 30.2%–30.7% (May 1, 2024) → raised 31.1%–31.6% (May 1, 2025) → raised 31.3%–31.6% (Aug 4, 2025) → raised 31.6%–31.8% (Nov 3, 2025) | 31.6% | within the range | -0.1 pts |
| FY2024 | 28.7%–29.0% (Aug 6, 2024) → reaffirmed 28.7%–29.0% (Oct 31, 2024) | 29.0% | within the range | +0.1 pts |
Tax rate
Met or beat 0 of 2 periods (2 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 1.0% (Feb 2, 2026) → reaffirmed 1.0% (May 5, 2026) → raised 1.3% (Aug 4, 2026) → reaffirmed 1.3% (Nov 2, 2026) | — | to be reported | — |
| FY2025 | 1.0% (May 1, 2024) → reaffirmed 1.0% (Feb 3, 2025) → reaffirmed 1.0% (May 1, 2025) → raised 1.2% (Aug 4, 2025) → raised 1.7% (Nov 3, 2025) | 20.0% | above the range | +18.3 pts |
| FY2024 | 1.0% (Aug 6, 2024) → reaffirmed 1.0% (Oct 31, 2024) | 20.0% | above the range | +19.0 pts |
EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $14.45–$14.90 (May 5, 2026) | — | to be reported | — |
| FY2024 | $10.31–$10.59 (Aug 6, 2024) → reaffirmed $10.37–$10.53 (Oct 31, 2024) | — | — | — |
| FY2025 | $10.82–$11.20 (May 1, 2024) → raised $11.74–$12.24 (Feb 3, 2025) | — | — | — |
Capital expenditures
The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $180M (Feb 2, 2026) → reaffirmed $180M (May 5, 2026) → reaffirmed $180M (Aug 4, 2026) → lowered $160M (Nov 2, 2026) | — | to be reported | — |
| FY2024 | $180M (Aug 6, 2024) → lowered $160M (Oct 31, 2024) | $121M (GAAP) | not judged | — |
| FY2025 | $180M (May 1, 2024) → lowered $160M (Feb 3, 2025) → reaffirmed $160M (May 1, 2025) → reaffirmed $160M (Aug 4, 2025) → lowered $140M (Nov 3, 2025) | $125M (GAAP) | not judged | — |
Interest expense
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $34.0M (Feb 2, 2026) → lowered $32.0M (Nov 2, 2026) | — | to be reported | — |
| FY2025 | $42.0M (Feb 3, 2025) | — | — | — |
The latest quarter
Idexx Laboratories, Q3 2026: revenue $1.2B (+10% year over year), operating margin 33.1%, net earnings $317M, operating cash flow $450M. The chart follows the revenue to costs, profit and cash.
Questions
Does Idexx Laboratories beat its guidance?
Idexx Laboratories gave guidance in 12 earnings releases on file since May 1, 2024. Of 6 guided periods since reported, it met or beat its own guidance 4 times (67%). Revenue: 2 of 2, on average +0.5% against the guided midpoint.
How often does Idexx Laboratories raise guidance?
Its earnings releases raised guidance 6 times and lowered it once since May 1, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.